Incretin-Based Drugs Market Report 2026

Incretin-Based Drugs Market Overview

• Incretin-Based Drugs market size has reached to $27.83 billion in 2025 • Expected to grow to $39.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: The Rising Prevalence Of Type 2 Diabetes Mellitus Is Fueling The Growth Of The Market Due To Increasing Cases Of Insulin Resistance And Pre-Diabetes • Market Trend: Development Of First Generic GLP-1 Agonist Enhances Access to Type 2 Diabetes Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Incretin-Based Drugs Market?

Incretin-based drugs are medications that manage type 2 diabetes by boosting the action of incretin hormones, which increase insulin release after eating. These drugs help control blood sugar levels, curb appetite, and promote weight loss. They also minimize the risk of sharp blood sugar spikes and typically do not cause severe hypoglycemia. The main types of incretin-based drugs are glucagon-like peptide-1 receptor (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. GLP-1 receptor agonists mimic natural GLP-1 to enhance insulin, suppress glucagon, slow gastric emptying, and reduce blood sugar in type 2 diabetes and obesity. It is administered through various routes of administration, such as oral and injectable, and is distributed through several distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies, for various applications, such as type 2 diabetes, obesity, and others.

What Is The Incretin-Based Drugs Market Growth Forecast?

The incretin-based drugs market size is expected to see strong growth in the next few years. It will grow to $39.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to global obesity epidemic, weight management drug demand, long-acting incretin innovation, personalized diabetes care, preventive metabolic health focus. Major trends in the forecast period include rapid adoption of glp-1 receptor agonists, expansion of obesity management indications, increased use of oral incretin therapies, growing combination therapy approaches, improved patient adherence through weekly dosing.

What Is The Driver Of The Incretin-Based Drugs Market?

The rising prevalence of type 2 diabetes mellitus is expected to propel the growth of the incretin-based drugs market going forward. Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to elevated blood glucose levels. The prevalence of Type 2 diabetes is due to poor diet, and inactivity causes insulin resistance, making the body less able to regulate blood sugar levels. Incretin-based drugs improve type 2 diabetes by boosting insulin release after eating and reducing glucagon production, helping to lower blood sugar. They also delay stomach emptying and curb appetite, aiding glucose control and weight loss. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, around 549,000 more people in England at risk of developing type 2 diabetes, raising the total number with pre-diabetes to over 3.6 million, a nearly 20% increase from 2022. Therefore, the rising prevalence of type 2 diabetes mellitus is driving the growth of the incretin-based drugs industry.

Key Players In The Global Incretin-Based Drugs Market

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Global Incretin-Based Drugs Market Trends and Insights

Major companies operating in the incretin-based drugs market are focusing on developing a generic drug version to offer more effective and patient-friendly treatment options for type 2 diabetes. A generic drug is a medication with the same active ingredients, strength, dosage form, and route of administration as a brand-name drug but is marketed under its chemical name without brand labeling. For instance, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. It received Food and Drug Administration (FDA) approval. It indicated it as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, providing a new, more affordable option amid ongoing shortages of GLP-1 medications.

What Are Latest Mergers And Acquisitions In The Incretin-Based Drugs Market?

In July 2024, Roche, a Switzerland-based pharmaceutical company, acquired Carmot Therapeutics for approximately $2.7 billion. This strategic move will strengthen Roche’s position in the rapidly growing obesity and metabolic disease market by integrating Carmot’s innovative injectable and oral therapies into its pharmaceuticals division. Carmot Therapeutics is a US-based clinical-stage biotechnology company that focuses on obesity and diabetes, with a particular emphasis on incretin-based therapies such as GLP-1 and GIP receptor agonists.

What Defines the Incretin-Based Drugs Market?

The incretin-based drugs market consists of sales of dual or multi-agonists, glucagon receptor co-agonists, and fixed-dose combination drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the drugs, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the drugs.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Incretin-Based Drugs Market Report 2026?

The incretin-based drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the incretin-based drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.